Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole was unchanged today. By the end of trading, Allergan fell $2.00 (-2.2%) to $90.26 on light volume. Throughout the day, 2,209,684 shares of Allergan exchanged hands as compared to its average daily volume of 3,079,300 shares. The stock ranged in price between $90.08-$92.07 after having opened the day at $92.07 as compared to the previous trading day's close of $92.26. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 37.9%,

Hyperion Therapeutics



), down 8.2%,

Chelsea Therapeutics International



), down 8.1% and

Merus Labs International



), down 6.9%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $27.1 billion and is part of the health care sector. Shares are down 0.2% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front,

Reliv' International



), up 54.8%,

Synta Pharmaceuticals



), up 41.3%,

Idera Pharmaceuticals



), up 38.0% and

GW Pharmaceuticals PLC ADR



), up 17.0% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.